RCT (randomized and placebo controlled), patient blinded
Adult patients (18 years < age < 80 years) with confirmed sepsis
Ulinastatin, 200,000 U 3 times/day for 3 days; a subcutaneous dose of Tα1, 1.6 mg, 2 times/day for 3 days followed by 100,000 U ulinastatin 3 times/day plus 1.6 mg Tα1 once/day for 4 successive days. Placebo in the same way.
For the first 3 days, 200K U ulinastatin and twice daily subcutaneous doses of 1.6 mg thymosin α1. For the next 4 days, intravenous doses of 100K U ulinastatin and twice daily subcutaneous doses of 1.6 mg thymosin α1. Placebo in the same way.
Adult patients (18 years < age < 80 years) with confirmed sepsis
200K U UTI 3 times per day plus a subcutaneous dose of 1.6 mg Tα1 twice a day for 3 days followed by a dose of 100K U UTI thrice a day plus 1.6 mg Tα1 once a day for four continuous days. Placebo in the same way.
Randomized and placebo controlled, patient blinded
Adult patients (18 years < age < 80 years) with confirmed sepsis
200K U UTI 3 times per day plus a subcutaneous dose of 1.6 mg Tα1 twice a day for 3 days followed by a dose of 100K U UTI thrice a day plus 1.6 mg Tα1 once a day for four continuous days. Placebo in the same way.
Adult patients (18 years < age < 80 years) with confirmed sepsis
200K U UTI 2 times per day plus a subcutaneous dose of 1.6 mg Tα1 twice a day for 4 days followed by a dose of 100K U UTI twice a day plus 1.6 mg Tα1 once a day for 6 continuous days. Blank control.